Company intelligence / Profile preview

Aster Medicines

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

Aster Medicines is an early-stage biotechnology company focused on targeted protein degradation (TPD). The company is leveraging small molecules to induce the degradation of disease-causing proteins that have been traditionally difficult to target with conventional inhibitors.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Partnerships

Ridgeline Discovery

Beyond the preview

Go deeper on Aster Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aster Medicines.

Explore the full profile